There is growing interest in stem cell‐derived exosomes for their therapeutic and regenerative benefits given their manufacturing and regulatory advantages over cell‐based therapies. As existing fibrosis impedes the viability and… Click to show full abstract
There is growing interest in stem cell‐derived exosomes for their therapeutic and regenerative benefits given their manufacturing and regulatory advantages over cell‐based therapies. As existing fibrosis impedes the viability and efficacy of stem cell/exosome‐based strategies for treating chronic diseases, here we tested the effects of the anti‐fibrotic drug, serelaxin, on the therapeutic efficacy of human amnion epithelial cell (AEC)‐derived exosomes in experimental lung disease.
               
Click one of the above tabs to view related content.